Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma

Bone Marrow Transplantation

Volumn 45, Issue 9, 2010, Pages 1396-1403

  Gertz, M A ^a   Wolf, R C ^a   Micallef, I N M ^a   Gastineau, D A ^a  

^a MAYO CLINIC   (United States)

Author keywords

growth factors; SCT; stem cell mobilization

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ANTIBIOTIC THERAPY; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CELL COUNT; CELL ISOLATION; DRUG DOSE INCREASE; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE UTILIZATION; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RESOURCE ALLOCATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT FAILURE;

EID: 77956469983     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.370     Document Type: Article

References (60)

1. Brice P. Managing relapsed and refractory Hodgkin Lymphoma. Br J Haematol 2008; 141: 3-13.
2. Wrench D, Gribben JG. Stem cell transplantation for non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2008; 22: 1051-1079, xi.
3. Mehta J, Singhal S. Current status of autologous hemato-poietic stem cell transplantation in myeloma. Bone Marrow Transplant 2008; 42 (Suppl 1): S28-S34.
4. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S et al. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant 2004; 34: 161-167.
5. Jansen J, Hanks S, Thompson JM, Dugan MJ, Akard LP. Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med 2005; 9: 37-50.
6. Gasova Z, Marinov I, Vodvarkova S, Bohmova M, Bhuyian-Ludvikova Z. PBPC collection techniques: standard versus large volume leukapheresis (LVL) in donors and in patients. Transfus Apher Sci 2005; 32: 167-176.
7. Gidron A, Singh V, Egan K, Mehta J. Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: what should the threshold required for apheresis be? Bone Marrow Transplant 2008; 42: 439-442.
8. Moog R. Mobilization and harvesting of peripheral blood stem cells. Curr Stem Cell Res Ther 2006; 1: 189-201.
9. Jillella AP, Ustun C. What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant? Stem Cells Dev 2004; 13: 598-606.
10. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
11. Sautois B, Fraipont V, Baudoux E, Fassotte MF, Hermanne JP, Jerusalem G et al. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica 1999; 84: 342-349.
12. Sheridan WP, Begley CG, To LB, Grigg A, Szer J, Maher D et al. Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105-111.
13. Erratum in: Bone Marrow Transplant 1995; 15: 654.
14. Putkonen M, Rauhala A, Pelliniemi TT, Remes K. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. Ann Hematol 2009; 88: 673-680.
15. Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J et al. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica 2008; 93: 1739-1742.
16. Weaver CH, Schulman KA, Buckner CD. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargram-ostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001; 27(Suppl 2): S23-S29.
17. Gazitt Y, Callander N, Freytes CO, Shaughnessy P, Liu Q, Tsai TW et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF, or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res 2000; 9: 737-748.
18. Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007; 9: 539-547.
19. Akhtar S, Weshi AE, Rahal M, Khafaga Y, Tbakhi A, Humaidan H et al. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin Lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008; 49: 769-778.
20. Carral A, de la Rubia J, Martin G, Molla S, Martinez J, Sanz GF et al. Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. Leuk Res 2003; 27: 5-12.
21. Ameen RM, Alshemmari SH, Alqallaf D. Factors associated with successful mobilization of progenitor hematopoietic stem cells among patients with lymphoid malignancies. Clin Lymphoma Myeloma 2008; 8: 106-110.
22. Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9-13.
23. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-596.
24. Desikan KR, Dhodapkar MV, Barlogie B. Waldenstrom's macroglobulinemia. Curr Treat Options Oncol 2000; 1: 97-103.
25. Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD et al. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93: 405-412.
26. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280-1281. (Pubitemid 351833803)
27. Mishra V, Andresen S, Brinch L, Kvaloy S, Ernst P, Lonset MK et al. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant 2005; 35: 1149-1153.
28. Boeve S, Strupeck J, Creech S, Stiff PJ. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997-1003.
29. Mishra V, Vaaler S, Brinch L. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol 2003; 25: 179-184.
30. Burgstaler EA, Pineda AA, Winters JL. Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator. J Clin Apher 2004; 19: 103-111.
31. Escalon MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M et al. Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone Marrow Transplant 2009; 44: 89-96.
32. Harousseau JL. Role of stem cell transplantation. Hematol Oncol Clin North Am 2007; 21: 1157-1174, x.
33. Watts MJ, Ings SJ, Flynn M, Dodds D, Goldstone AH, Linch DC. Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. Br J Haematol 2000; 111: 287-291.
34. Prajogo J, Neil A, Duke J, Zhang H, Stokes B, Rowlings P. Modelling cost-effectiveness of high-dose chemotherapy as treatment for relapsed aggressive non-Hodgkin lymphoma in an Australian setting. Intern Med J 2009; 39: 519-526.
35. Meehan KR, Hill JM, Patchett L, Webber SM, Wu J, Ely P et al. Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization. Transfusion 2006; 46: 523-529.
36. Jacoub JF, Suryadevara U, Pereyra V, Colon D, Fontelonga A, Mackintosh FR et al. Mobilization strategies for the collection of peripheral blood progenitor cells: results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Exp Hematol 2006; 34: 1443-1450.
37. Hart C, Grassinger J, Andreesen R, Hennemann B. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells. Bone Marrow Transplant 2009; 43: 197-206.
38. Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, Varettoni M et al. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion 2008; 48: 857-860.
39. Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 743-750.
40. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43: 619-625.
41. 2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278-282.
42. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-3785.
43. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33-36.
44. Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients: results of a phase I/II trial. Blood 1997; 89: 3136-3147.
45. Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P et al. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome: a retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009; 41: 33-37.
46. Callera F, Cavenaghi L, de Melo CM. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: a feasible strategy for multiple myeloma or pre-treated non-Hodgkin's lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF. Transfus Apher Sci 2009; 40: 91-95.
47. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000; 18: 43-53.
48. Rick O, Beyer J, Kingreen D, Kuhl JS, Zingsem J, Huhn D et al. Successful autologous bone marrow rescue in patients who failed peripheral blood stem cell mobilization. Ann Hematol 2000; 79: 681-686.
49. Lefrere F, Levy V, Makke J, Audat F, Cavazzana-Calvo M, Miclea JM. Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure. Haematologica 2004; 89: 1532-1534.
50. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-744.
51. Marit G, Thiessard F, Faberes C, Cony-Makhoul P, Boiron JM, Bernard P et al. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study. Leukemia 1998; 12: 1447-1456.
52. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.
53. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. 3102 investigators plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
54. Sartor MM, Garvin F, Antonenas V, Bradstock KF, Gottlieb DJ. Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraft-ment after autologous stem cell transplantation. Bone Marrow Transplant 2007; 40: 851-857.
55. Stewart DA, Smith C, MacFarland R, Calandra G. Pharmaco-kinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 39-46.
56. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009; 15: 249-256.
57. Wagstaff AJ. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma. Drugs 2009; 69: 319-326.
58. Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM, Markovic SN. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002; 117: 629-633.
59. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lym-phoma. Blood 2001; 98: 579-585.
60. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hemato-poietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 291-298.